TIME EUROPE
January 15, 2000, Vol. 157 No. 2
The Hunt for Cures
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
The accidental discovery in the 1950s of the first synthetic tranquilizer, chlorpromazine (Thorazine), ushered in a gentler age of psychopharmacology. As other feel-good pills followed — Tofranil (imipramine) for depression, Miltown and Equanil (meprobamate) for psychosis, Valium (diazepam) for severe anxiety and lithium for manias — no mental illness seemed beyond their reach. Governments began emptying mental wards on the assumption that madness could be medicated — ignoring the fact that thousands of former inmates ended up living, and suffering, in the streets.
By the time Prozac (fluoxetine) swept onto the stage in 1988, the new drugs had wrought a revolution in psychiatry. Long-drawn-out talking cures were shortened or replaced by prescription pills, and some doctors found their offices filled with grateful patients. "All of a sudden, we were being told, 'Gee, doc, you're great,'" recalls Dr. Samuel Barondes, a psychiatrist and medical historian at the University of California, San Francisco. No one really understood how the wonder pills worked. Nor were they always free of distressing side effects — such as the "Thorazine shuffle," the stumbling, zombie-like gait that often accompanies this treatment for schizophrenia.
Still, the message out of the bottle was clear: Forget the couch; there is no psychiatric ill that cannot be chemically controlled. Even hyperactive youngsters were caught up in the pharmacological whirlwind, given daily doses of Ritalin to tame their excess energies. Critics such as Dr. Thomas Szacz worried loudly about an overly medicated, drug-dependent society. But with more than 50 million Americans suffering from mental illnesses of varying degrees of severity, doctors in the clinical trenches felt they had no choice but to employ the best weapons at their disposal. Says Dr. Sophia Vinogradov, Barondes' ucsf colleague and a specialist in schizophrenia: "We now have a much more vigorous armamentarium for our patients."
Her armamentarium will soon grow. No fewer than 103 new psychoactive drugs are currently undergoing testing, including clinical trials, according to the Pharmaceutical Research and Manufacturers of America. These include 26 drugs for depression, a disease that affects 19 million Americans each year and costs the country more than $23 billion in lost work days and decreased productivity. Other drugs in the pipeline target schizophrenia, anxiety phobias and various forms of senile dementia, most notably Alzheimer's. All told, drug companies are betting $6 billion a year on R. and D. in hopes of creating new blockbuster drugs like Eli Lilly's Prozac, whose patent expires in 2003.
It's a long shot. Only 1 out of 5,000 potential drugs makes it from the lab to the medicine chest (a process that can take as long as 15 years). But the odds are better now than when tranquilizers came largely from inspired guesswork. Computerized brain scans, dna probes and other technological wizardry have given drugmakers powerful new tools for understanding at a molecular level the brain's inner workings — and how chemicals affect them.
Consider schizophrenia, which strikes 1% to 2% of the world's population, including 3 million Americans, usually in their late teens or early 20s. Over the years, its harrowing symptoms — hallucinations, persistent voices, paranoia and frozen emotions — have been blamed on everything from witchcraft to the evil eye. Now scientists realize that schizophrenia is a complex syndrome resulting from the failure of various neurotransmitters — the chemical messengers that skip from one nerve cell to the next — including dopamine, serotonin and 5-hydroxytryptamine. "Certainly it's not caused by bad parenting," says Vinogradov. Knowing which neurotransmitters are implicated in the disease gives drugmakers precise targets around which to design better anti-schizophrenia compounds.
Prozac is another drug that targets a particular neurotransmitter, plugging up brain chemicals that absorb the mood elevator called serotonin. Competing ssris (selective serotonin reuptake inhibitors), as they're called, include Lilly's duloxetine and Solvay Pharmaceuticals' fluvoxamine. Both drugs affect the same biochemical pathways, only with greater precision and fewer side effects. But better ssris aren't the only new approach. Sanofi-Synthelabo is looking into the potential of a so-called mao (monoamine oxidase) inhibitor called befloxatone. Monoamine oxidase is another serotonin-disrupting enzyme, so anything that inhibits it should make more of the mood-elevating chemical available to the brain cells.
Many of the new drugs are old drugs turned to different uses. The National Institute on Drug Abuse has five compounds under review for use against cocaine dependence, all of them originally developed for treating Parkinson's disease — a good example of how different neurological disorders can have common biochemical threads. Researchers are also trying to fashion drugs that release their essential ingredients more slowly, over a period of weeks rather than hours or days, eliminating the need for daily pills or injections. That would make life easier for deinstitutionalized street people and embarrassed kids who must leave the classroom each day to get their Ritalin from the school nurse.
The biggest payoff may come from understanding the genetics of mental illness. Using gene-chip technology, a team at the University of Pittsburgh School of Medicine recently spotted the same mutation in the dna of 10 schizophrenic patients. The flaw was in a gene on chromosome 1 called rgs4, which controls the duration of signals in a nerve cell. Intriguingly, the mutation showed up in the brain's visual, motor and cognitive centers. That could account for schizophrenics' hallucinations and attention problems, says team leader Pat Levitt.
MORE >>
For more stories from TIME's special report, check out time.com/health
This edition's table of contents
TIME Europe home
More stories from TIME Europe and related links
E-mail us at mail@timeatlantic.com
Like what you're reading?
Click here to try 4 FREE ISSUES of TIME
|
|
|
|
COVER STORY
Special Report: The Future of Medicine
With the mapping of the human genome the process by which new drugs are developed is being turned upside down. These drugs will also change our lives
Brave New Pharmacy
Using high-speed robots and the secrets of the human genome, scientists are changing forever the way they discover new medicine
The Hunt for Cures
Genetic information could lead to treatments for everything from AIDS to obesity
EUROPE
Prague Winter
When Jiri Hodac was named director of state television, Czech journalists saw a return to government meddling in the media
See Vous in Court
France is the latest nation to join the litigation game
Going up in Smoke
Switzerland, land of luxury watches and bank secrecy, has a new growth industry: marijuana
UNITED STATES
The True Blue Bush Cabinet
Its ethnic and gender balance is correct, but can a divided nation deal with the superconservative bent?
BUSINESS
Transparency has its Price
Executives at many German companies are finding it hard to adjust to the more rigorous financial disclosure required by global investors
On Spreading the Word
When it comes to selling merchandise, word-of-mouth marketing may be a company's best weapon
Essay: Meat Matters
Critics of industrialized farming may be forgetting about world hunger, writes TIME's Rod Usher
THE ARTS
Rebel with a Cause
The real-lifestory of an anti-Mafia activist in Sicily makes for a handsome film with a political message
The Upmarketeer's Tale
Bernard Arnault built his house by selling at deluxe prices and in his book he's still giving nothing away
The Art of Noise
For Europe's freely improvised music, the only rule is no rule
DEPARTMENTS
Techwatch
World Watch
WHAT DO YOU THINK?
E-mail us at mail@timeatlantic.com
|
|
